Mr. Zweigenhaft, an industry thought leader and accomplished executive in the specialty-biotech pharmaceutical and oncology cancer care ecosystem.
Mr. Zweigenhaft’s primary role in CureVax is guiding the Founders and the Company through the business development process while securing funding and commercialization partnerships to growth.
Mr. Zweigenhaft is also the Managing Partner of BioPharma Partners which is a New York and Washington DC based strategy and early stage development company focused on incubating new healthcare services, bio-pharmaceuticals, Precision Medicine and Digital Health Technologies into the healthcare ecosystems. Mr. Zweigenhaft guidance has supported market strategies with industry leaders such as Genzyme, Pharmacyclics, Gilead, Janssen, Alexion, Bayer, GSK, Monogram Science, Roche, Genentech, and Genomic Health as well as many of the healthcare payers the likes of Aetna, Cigna, Cancer Treatment Centers of America and several of the Blue Cross Blue Shield plans.
Previously Mr. Zweigenhaft was the Founder, CEO and Vice Chairman of Onco360 a national oncology pharmacy care management provider with corporate offices in New York City. Onco360 provides the full continuum of oncology pharmacy service solutions to over 3,000 community based Hematologists and Oncologists and Hospital Based Cancer Centers of Excellence in coordination with managed care providers insuring over 45 million people. Under Mr. Zweigenhaft’s vision and leadership Onco360 developed and implemented the current industry best practice oncology pharmacy model by incorporating the strengths of Board Certified Oncology Pharmacists and Oncology Patient Advocates to support the prospective and concurrent patient centered oncology medical home model. In 2014 PharMerica acquired controlling interest in Onco360 and relocated the Company in 2015 to Louisville, KY.
Mr. Zweigenhaft previously served as Senior Vice President of Managed Care Sales and Marketing, Government Programs, Trade Relations and Business Development Strategies for Priority Healthcare Corporation, a publicly traded company in the specialty pharmacy sector with $2.3 billion in specialty drug revenues before being acquired by Express Scripts in 2005.
Prior to 2002, Mr. Zweigenhaft spent several years serving as a specialty pharmacy consultant to Medco, CuraScript, BioScrip and several Regional and National Blue Cross Blue Shield and National Managed Care Payer programs.
Mr. Zweigenhaft holds a Bachelor of Science in Management and Economics from the University of Buffalo School Of Management, where he also serves on the Dean’s Advisory Committee and remains active with the University of Buffalo schools of Pharmacy and Medicine including the Center of Excellence for Bio-Informatics and Health Sciences. Mr. Zweigenhaft is a member of AMCP (American Managed Care Pharmacy), HOPA (Hematology Oncology Pharmacists Association) and ASCO (American Society of Clinical Oncologists). Mr. Zweigenhaft also serves on the Editorial Boards of several industry publications and is Editor and Chief of the Journal for Value Based Cancer Care. Mr. Zweigenhaft is also Co-Chairman and Co-Founder of the Association for Value Based Cancer Care and serves as a Board Member of and Vice President of NASP (National Association of Specialty Pharmacy) in Washington, DC.
Philanthropically, Mr. Zweigenhaft also serves on the National Board of Swim Across America for Cancer; a charitable organization that has raised $70 million to date to support cancer research laboratories. Just recently on April 22, 2015 Mr. Zweigenhaft was recipient of the CancerCare “Help and Hope Award”.
Dr. Tiwari is a Cancer Biologist with over 30 years of Cancer research in Molecular Biology and Immunology. He is a Professor of Microbiology and Immunology, the Graduate Program Director, New York Medical College. An accomplished scientist of international repute has over 200 publications and abstracts, is a leader in cancer prevention and control and inventor of several patents involving Capridine with Cancer Vaccines. Dr.Tiwari was Assistant Professor of Biochemistry in Surgery, Cornell University Medical College (1991-1996), New York, and Assistant Laboratory Member for the Sloan-Kettering Institute for Cancer Research (1989-1991). During the same period he served as Assistant Attending Biochemist for Memorial Hospital, Breast Service. Dr. Tiwari has a Ph.D. in Biochemistry from Calcutta University and received his post-doctoral training at the University of Toronto, Canada (1984-1985) and then at Sloan-Kettering Cancer Institute, New York (1986-1989). In addition to his academic appointments, Dr. Tiwari reviews grant applications for the American Cancer Society, the American-Italian Foundation, the Dutch Cancer Society, and the Governments of Israel and Italy.
Dr. Tiwari has published over two hundred scientific articles, primarily in cancer biology. Dr. Tiwari has been honored a number of times for his scholarship, including: (i) National Scholarship, Government of India (1972-1979); (ii) Junior Research Fellowship, Indian Council of Medical Research (1979-1982); (iii) Senior Research Fellowship, Indian council of Medical Research (1982-1983); (iv) Post-Doctoral Fellowship, University of Toronto (1983-1985); and (v) Post- Doctoral Fellowship, the National Institute of Health (1992). He is the author of several awarded patents.
Dr. Tiwari is a member of the American Association for Cancer Research, the American Association for the Advancement of Science, the Society for Interferon Research, the Harvey Society and the New York Academy of Sciences. Dr. Tiwari is also a member of the Molecular Biology Study Section which reviews and awards grants for breast cancer from the US Army Medical Research Command. Dr. Tiwari research has been funded by grants from the National Institute of Health (NIH), the US Army Medical Research Command (Breast and Prostate Cancer Initiative), and the American Institute for Cancer Research. Dr. Tiwari is a co –founder of CureVax and holder of several patents related to cancer discovery products.
Dr. Geliebter brings to the Company a wide range of immunology, genetics and cancer research experience to continue the company’s future growth. His experience includes research of prostate cancer, thyroid cancer, vaccines for infectious diseases and melanoma.
Dr. Geliebter is the Professor of Microbiology and Immunology, Associate Professor of Otolaryngology and the Medical Microbiology Course Director at New York Medical College. Dr. Geliebter joined New York Medical College as the Assistant Professor of Microbiology and Immunology in 1966. Previously Dr. Geliebter was the Assistant Professor of Urology at Albert Einstein College of Medicine 1993 through 1996. Dr. Geliebter also held the position of Assistant Investigator for the Howard Hughes Medical Institute from 1988 to 1993. During this period of time Dr. Geliebter was also Assistant Professor at the Rockefeller University. Early in his career Dr. Geliebter served as a Post Doctorial Fellow and Research Associate at the Albert Einstein College of Medicine from 1981 to 1988 In addition to his academic appointments, Dr. Geliebter serves as an ad hoc reviewer for the periodicals: Cancer, Journal of Urology, Cancer Investigation, Cancer, Cancer Biology and Therapy, Peptides, Cancer Epidemiology, Biomarkers and Prevention, Medical Oncology, Journal Cellular Physiology, Soc Exp Biol, Med, Clinical Cancer Research, Nature Reviews Urology, Oncogene, and Int. J Cancer Dr. Geliebter is very active in a wide range of educational activities at the New York Medical College on the graduate level and the medical school. Dr. Geliebter has published over 100scientific articles. He has been awarded four patents and currently has one patent pending. Dr. Geliebter has been honored for his scholarship by the American Cancer Society, National Cancer Institute, Albert Einstein College of Medicine, Pfeiffer Foundation, and New York Medical College. Dr. Geliebter holds a PhD in Microbiology and Immunology from SUNY, Downstate Medical Center.
Dr. Geliebter is a member of the American Association for Cancer Research, the American Association for the Advancement of Science, and the New York Academy of Sciences. His research has been funded by grants from the Pfeiffer Foundation, American Institute for Cancer Research, Retirement Research Foundation, National Institute of Health, and the National Cancer Institute. Dr. Geliebter is a co-founder of CureVax and holder of several patents relative to cancer discovery products.
Research Board Members
Dr. Kolchin received his MD and PhD from the Medical School and the Department of Microbiology at SUNY Downstate Medical Center. Dr. Kolchin’s internship and residency training was followed by a Clinical and Research Fellowship in Allergy and Clinical Immunology at Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. In addition to basic science and translational research experience, Dr. Kolchin’s clinical research experiences includes serving as clinical trial Medical Monitor, reviewing and evaluating study protocols and clinical study reports, medical review of clinical trial data listings and clinical narrative writing.
Dr. Robert Suriano earned his Bachelor’s of Science degree in pre-medical sciences from Manhattan College, Riverdale, NY in 2001 after which he enrolled in the doctoral program in the department of Microbiology and Immunology at New York Medical College, Valhalla, NY. During his doctoral studies at New York Medical College, Dr. Suriano’s dissertation research focused on cancer biology, specifically understanding the relationship between cancer formation and aberrant glycosylation of heat shock proteins. In 2007, Dr. Suriano was awarded a Doctor of Philosophy and subsequently completed three years of post-doctoral training at New York Medical College. In 2010, Dr. Suriano joined the faculty of the Department of Microbiology and Immunology at New York Medical College as a Research Assistant Professor. While at New York Medical College, both as a student and faculty member, Dr. Suriano authored over 20 research articles in peer reviewed journals. In addition to the research articles published, Dr. Suriano published over 40 abstracts, which were presented at various international meetings sponsored by organizations such as the American Association for Cancer Research.
Scientific Advisory Board
See a list of all the Scientific Advisory Board members at CureVax.View Now